JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (8): 52-56.doi: 10.6040/j.issn.1671-7554.0.2013.701

Previous Articles     Next Articles

Clinical observation of triple therapy of moxifloxacin and esomeprazole magnesium for Helicobacter Pylori

WANG Hui   

  1. Department of Gastroenterology, Hospital of Shandong Institute of Business and Technology, Yantai 264005, Shandong, China
  • Received:2013-11-22 Revised:2014-07-03 Online:2014-08-10 Published:2014-08-10

PDF (PC)

126

Abstract: Objective To evaluate the efficacy of triple therapy of moxifloxacin and esomeprazole magnesium to eradicate Helicobacter pylori (Hp). Methods A total of 126 patients were randomly divided into moxifloxacin group and control group. The moxifloxacin group was treated with moxifloxacin, esomeprazole and clarithromycin, while the control group was treated with omeprazole, amoxicillin and clarithromycin. Both treatments lasted for 2 weeks. One month after the treatment, the patients undertook endoscopic examination (pathological biopsy), rapid urease test and 13carbon/14 carbon urea breath test (13C/14C-UBT). The adverse drug reactions and compliance were observed. Results In intention to treat (ITT)analysis, the Hp-eradication rate was 75.0% in the moxifloxacin group, and 58.1% in the control group (P<0.05); in per protocol (PP) analysis, the Hp-eradication rate was 92.3% in the moxifloxacin group, and 69.2% in the control group (P<0.05). However, in the adverse drug reaction and compliance comparison analysis, there was no statistical difference between the two groups (P>0.05). Conclusion The triple therapy based on moxifloxacin and esomeprazole is highly effective to eradicate Hp infection, with no significant difference in the adverse drug reaction and compliance from the conventional triple therapy; therefore, it is worth of clinical spread.

Key words: Combination, Helicobacter pylori, Drug therapy, Moxifloxacin, Esomeprazole magnesium

CLC Number: 

  • R573
[1] 董玉柱.以莫西沙星、埃索美拉唑镁为核心的三联疗法治疗一线、补救治疗失败的幽门螺杆菌感染的临床观察[J].临床合理用药杂志，2011,4(2)：8-9.
[2] 许静，高日金，孟云霞，等. 埃索美拉唑配合莫西沙星和克拉霉素根除幽门螺旋杆菌疗效观察[J].内蒙古中医药，2011,30(14)：92-93.
[3] 詹春光，李健.莫西沙星三联疗法根除幽门螺杆菌感染的临床研究[J].实用医学，2010,26(6)：1032-1033.
[4] 中华医学会消化病学分会幽门螺杆菌学组/幽门螺杆菌科研协作组.第三次全国幽门螺杆菌感染若干问题共识报告[J].胃肠病学，2008，13(1)：42-46.
[5] 辛磊，李兆申.氯吡格雷与质子泵抑制剂联合应用的不良反应研究进展[J].中华内科，2010,49(10)：899-890.
[6] 周丽丽. 质子泵抑制剂致不良反应因素分析[J].中国药业，2013,22(10)：899-890.
[7] 王承党，庄则豪，陆岽，等.含莫西沙星三联方案根除幽门螺杆菌的疗效观察[J].中华医学，2010,90(2)：87-89.
[8] Bago J, Pevec B, Tomic＇ M, et al. Second-1ine treatment for Helicobacter pylori infection based on moxifloxaein triple therap: a randomized controlled trial[J]. Wien Klin Wochenschr, 2009, 121(1-2):47-52.
[9] 李娜，聂占国. 幽门螺旋杆菌对抗生素耐药现状及其机制研究进展[J].山东医药，2013,53(16)：85-88.
[10] Rimbar E, Noguchi N, Kawai T, et al. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB[J]. Helicobacter, 2012, 17(1):36-42.
[11] Cattoir V, Nectoux J, Lascols C, et al. Update on fluroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first descrip tion of a gyrApolymorphism associated with hypersusceptibility[J]. Int J Antimicrob Agents, 2007, 29(4):389-396.
[12] 郑小丽，许乐. 含莫西沙星三联疗法对幽门螺杆菌根除失败的补救治疗[J].中华医学，2010,90(2)：83-86.
[13] 黄秀萍，黄荣富，钟能能，等.质子泵抑制剂的应用分析[J].临床合理用药，2011,4(12A):60-61.
[14] Sugimoto M, Nishino M, Kodaira C, et al. Characteristics of nonerosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy[J]. World J Gastroenterol, 2011, 17(14):1858-1865.
[15] Malfertheiner P, Megraud F, O'Morain C, et al. Current concepta in the management of Helicobacter pylori infection： the Maastricht III Consensus Report[J]. Gut，2007, 5(6):772-781.
[16] 肖琼怡，王建刚，刘海，等.莫西沙星三联方法根除幽门螺杆菌的成本-效果分析[J].山西医药，2010,39(3)：270-271.
[1] LI An, CHEN Fengzhe, WANG Zheng, MENG Xiangzhu, XU Nannan, MA Lixian. In vitro synergy testing of sitafloxacin, cefoperazone-sulbactam and polymyxin E against extensively drug-resistant Acinetobacter baumannii [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 82-85.
[2] CUI Yong, ZHANG Rongxiang, WANG Fuli, WANG Guoying, FENG Jianlin, ZHANG Haixia. Clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of TP regimen for advanced ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 53-57.
[3] LUO Yumeng, YANG Hongbo, ZHU Huijuan, PAN Hui, ZENG Xianwei. Clinical analysis of 42 adults with childhood-onset adult growth hormone deficiency [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(10): 62-65.
[4] XU Cui, WANG Tao, ZHOU Ping. Immunohistochemical analysis of Helicobacter pylori infection in children [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 81-84.
[5] LI Yueyue, ZUO Xiuli, JI Rui, CHEN Feixue, ZHAO Hongyu, WANG Han, GUO Jing, ZHANG Jingyuan, FU Shanshan, LIU Jianwei, LI Yanqing. A randomized clinical trial of ten-day concomitant, sequential and bismuth-based quadruple therapies for Helicobacter pylori [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(7): 45-49.
[6] YANG Xue, QIU Chunhua, LEI Lei, HU Xiao. Characteristics of gastric polyps and correlation with helicobacter pylori infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 41-44.
[7] LI Tao1, LI Yu1, WANG Wen1, ZHANG Fan2, GU Teng-zhen3. Drug sensitivity of carbapenems combined with sulbactam or cefoperazone on Pseudomonas Aeruginosa [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(8): 65-68.
[8] . Antibiotics in reducing resistant mutants of Pseudomonas 
aeruginosa in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(9): 25-27.
[9] GUO Chun, WUN Na, HONG Hai-Jie, WU Wen-Liang, HE Jing, YU Bao-Fa, GAO Shangxian, HU Bao-Fang. Non-cell corynebacterium parvum product combined with slow intra-tumorr  elease of drugs inhibits B16 melanoma in mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(5): 67-70.
[10] HAN Chun-yan,SHENG Wei,HAN Jun-qing. Capecitabine combined with late course accelerated hyperfractionatedradiotherapy for esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(4): 427-429.
[11] FU Wei-jiang,YANG Qiu-an,HAN Wen-fei,FU Lei,GAO Shuang,PAN Zhen-hua,CHENG Xiao-guo. Clinical effect of concurrent chemoradiotherapy foradvanced esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(1): 84-87.
[12] HAO Jing,WANG Xiu-mei,YI Cui-hua,LI Li,WANG Xiu-wen,SUN Li-mei,YU Jin-ming. Health economical evaluation of four thirdgeneration chemotherapy regimens in advanced nonsmall lung cancer patients in China [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(6): 616-620.
[13] WEI Hong,LI Jin-song,LIU Wen-jun. Expression and significance of c-kit in conventional osteosarcoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(3): 243-245.
[14] BU Jie-qiong,YU Bao-fa. Slow intra-tumor release of drugs on B16 melonoma in mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 988-991.
[15] ZHANG Mei,ZHANG Yun,ZHAO Yu-xia,ZHANG Yuan-yuan,GAO Yue-hua,LI Xiu-chang. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(7): 662-665.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd